Premium
Pulmonary disease and antipyrine clearance
Author(s) -
Laybourn Carsten,
Tønnesen Philip,
Loft Steffen,
Sonne Jesper,
Døssing Martin
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.199
Subject(s) - medicine , clinical pharmacology , pulmonary function testing , pulmonary disease , lung , saliva , microsome , lung function , gastroenterology , pharmacology , enzyme , chemistry , biochemistry
We investigated hepatic microsomal enzyme activity by the one‐sample saliva test for antipyrine clearance determination in 35 homozygous, α 1 ‐antitrypsin‐deficient outpatients with chronic pulmonary disease. Twenty‐five outpatients with chronic obstructive lung disease and comparable lung function impairment and 31 healthy volunteers served as controls. Antipyrine clearance did not differ significantly between the two groups of patients with pulmonary disease. However, the clearance was 18% lower in these two groups than in the healthy volunteers (P < 0.01). Antipyrine clearance was lowest in patients with severe lung function impairment (P < 0.01). Clinical Pharmacology and Therapeutics (1986) 40, 415–419; doi: 10.1038/clpt.1986.199